Article
Actin-Resistant DNase1L2 as a Potential Therapeutics for CF Lung Disease
10 Mar 2021
Abstract excerpt
In cystic fibrosis (CF), the accumulation of viscous lung secretions rich in DNA and actin is a major cause of chronic inflammation and recurrent infections leading to airway obstruction. Mucolytic therapy based on recombinant human DNase1 reduces CF mucus viscosity and promotes airway clearance. However, the marked susceptibility to actin inhibition of this enzyme prompts the research of alternative treatments...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
